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Objective. To determine if the perfusion parameters by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of
regional nodal metastasis are helpful in characterizing nodal status and to understand the relationship with those of primary tumor
of nasopharyngeal carcinoma (NPC).Materials and Methods. Newly diagnosed patients imaged between August 2010 and January
2014 and who were found to have enlarged retropharyngeal/cervical lymph nodes suggestive of nodal disease were recruited. DCE-
MRI was performed.Three quantitative parameters,𝐾trans, Ve, and 𝑘ep, were calculated for the largest node in each patient. Kruskal-
Wallis test was used to evaluate the difference in the parameters of the selected nodes of different N stages. Spearman’s correlation
was used to evaluate the relationship between the DCE-MRI parameters in nodes and in primary tumors. Results. Twenty-six
patients (7 females; 25∼67 years old) were enrolled. 𝐾trans was significantly different among the patients of N stages (N1, 𝑛 = 3;
N2, 𝑛 = 17; N3, 𝑛 = 6), 𝑃 = 0.015. Median values (range) for N1, N2, and N3 were 0.24min−1 (0.17∼0.26min−1), 0.29min−1
(0.17∼0.46min−1), and 0.46min−1 (0.29∼0.70min−1), respectively. There was no significant correlation between the parameters in
nodes and primary tumors. Conclusion. DCE-MRI may play a distinct role in characterizing the metastatic cervical lymph nodes
of NPC.
1. Introduction
Nasopharyngeal carcinoma (NPC) is an aggressive head
and neck cancer with a high incidence in Southern China
including Hong Kong. Accurate staging using the Interna-
tional Union Against Cancer (UICC) tumor-node-metastasis
(TNM) staging system is critical for treatment planning and
the prediction of patient outcome [1–3]. Regardless of the
status of the primary lesion, nodal metastasis is a signifi-
cant prognostic factor for survival [4]. Hence the accurate
detection and the characterization of metastatic nodes are of
paramount importance in NPC patient management.
DCE-MRI is a functional imaging modality that has the
potential to characterize perfusion andmicrocirculation and,
thus, may have a role to play as a noninvasive biomarker
of cancer. The three quantitative parameters 𝐾trans, Ve, and
𝑘ep derived by DCE-MRI are frequently used. 𝐾
trans (in
minute−1) is the volume transfer constant of contrast agent
from blood plasma to extravascular extracellular space (EES)
reflecting both blood plasma flow and permeability, Ve is
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the volume of EES per unit volume of tissue, and 𝑘ep (in
minute−1) is the flux rate constant of contrast agent from
EES to plasma and equal to 𝐾trans/Ve [5]. Studies have found
DCE-MRI to be useful in differentiating diseased nodes from
normal nodes in head and neck squamous cell cancer, breast
cancer, and cervical cancer [6–8]. In these studies, it has been
shown that, in malignant nodes, microvascular permeability
and the extravascular extracellular space are increased.
In our previous study we have reported the feasibility of
applying DCE-MRI in NPC [9]. Our findings suggest that
the evaluation of DCE-MRI by both semiquantitative and
quantitative methods is useful in characterizing the neovas-
culature and permeability of NPC tumors. However only pri-
maryNPC tumors were studied. In the present study, we have
included the evaluation of regional metastatic nodes using
DCE-MRI. Since previous studies have reported increased
microvascular permeability in tumors or diseased nodes
(Padhani et al., 2000; Yao et al., 2011; Chang et al., 2008),
we hypothesized that nodal DCE-MRI parameters, which
reflect the microvascular permeability in regional metastatic
lymph nodes, correlate with nodal stage and the DCE-MRI
parameters in the primary tumor which is an indicator of
tumor aggressiveness.
2. Materials and Methods
2.1. Patients. This study was approved by the Institutional
Review Board of The University of Hong Kong/Hospital
Authority Hong Kong West Cluster. All consecutive newly
diagnosed NPC patients referred to the MRI Unit at The
University of Hong Kong between August 2010 and January
2014 were prospectively included. Patients with presumed
metastatic regional lymph nodes, based on enlarged lymph
nodes (>1 cm short axis diameter) on MRI, and supported
by increased metabolic activity on 18F-FDG PET-CT scans
(nodal SUVmax> 2.5) performedwithin oneweek of theMRI
scans, were included.The final diagnosis of metastatic lymph
nodes and the N stage were achieved by both the imaging
findings (MRI and PET-CT) and histological results. Written
informed consent was obtained for all patients. TNM staging
was performed according to the Joint Committee on Cancer
(AJCC) staging system [10].
2.2. DCE-MRI Techniques. After routine structural MRI
acquisition, DCE-MRI of the nasopharynx and upper neck
was performed on a 3.0-T MRI system (Achieva; Philips
Healthcare). Four acquisitionswere obtained in a chronologi-
cal orderwith a field of view (FOV) of 22× 22× 6 cm (AP×RL
× FH): precontrast T1-weighted fast field echo (FFE) acqui-
sition using a flip angle of 5∘ (“FA5” acquisition) in 1 minute
22 seconds; T2-weighted imaging (“T2W” acquisition) in 50
seconds; B1 mapping measurement acquisition (“B1MAP”
acquisition) in 1 minute 23 seconds; and DCE acquisition
using a flip angle of 15∘ (“FA15” acquisition) in 6 minutes 47
seconds with 65 dynamic scans. The details of scanning pro-
tocols have been described in our previous paper [9]. All four
acquisitions were performed in the same anatomical region
and reconstructed to the same resolution. The contrast agent
Gd-DOTA (Dotarem, Guerbet, France) was injected intra-
venously as a bolus into the blood at around the 8th dynamic
acquisition using a power injector system (Spectris Solaris,
MedRad,USA), immediately followed by a 25-mL saline flush
at a rate of 3.5mL per second. The dose of Gd-DOTA was
0.1mmol/(kg body weight) for each patient.
2.3. Data Analysis. All the acquired DCE-MRI images were
used for quantitative analysis, and the parametric maps of
𝐾
trans, 𝑘ep, and Ve were calculated as in our previous pub-
lication [9]. The procedure of calculating parametric maps
of𝐾trans, 𝑘ep, and Ve was performed using the software dcem-
riS4 http://cran.r-project.org/web/packages/dcemriS4/) devel-
oped byWhitcher and Schmid [11]: firstly themaps of contrast
concentration of 65 time points were calculated from the
DCE-MRI images and secondly for each voxel the contrast
concentration curve and the population AIF [9] were fitted
to the pharmacokinetic model to calculate the maps of the
three parameters.
For each patient, since there are usually more than 1
metastatic node, as done in the literature [12–14], the largest
metastatic node within the scanned region determined by
the sum of long and short of axis was identified by a neu-
roradiologist (PL Khong) based on conventional anatomical
MR images (T1-weighted, T2-weighted, and postcontrast T1-
weighted) and treated as the representative node in our study.
The node boundary was identified in the relevant consecutive
slices of the T2W images of DCE-MRI scan and a series of
two-dimensional regions of interest (ROI) were contoured
using the software ImageJ (NIH, USA) (V Lai). The average
𝐾
trans, 𝑘ep, and Ve values in each node were calculated and
used for further analysis.
The normality of the DCE-MRI parameters distribution
in our cohort was checked using Shapiro–Wilk test. ANOVA
(for data of normal distribution) or Kruskal-Wallis test (for
data which are not normal distribution) were used to evaluate
the difference among tumor N stages. Pearson’s correlation
(for data of normal distribution) or Spearman’s correlation
(for data which are not normal distribution) was performed
to study the correlations between the DCE-MRI parameters
in nodes and in primary tumors and between the DCE-MRI
parameters in nodes and nodal size. All statistical analyses
were performed using SPSS 20 (SPSS Inc, Chicago, IL, USA),
and 𝑃 < 0.05 was considered statistically significant.
3. Results
Thecohort characteristics of this study are shown inTable 1. A
total of 26 patients were included and 7 of them were female.
Themean age was 45 years (range, 25∼67 years; SD, 12 years).
The correlations between the DCE-MRI parameters in nodes
and nodal size are insignificant with all 𝑃 values higher than
0.2.
By Kruskal-Wallis test, 𝐾trans in the largest node of each
patient was significantly different among the various N stages
(𝑃 = 0.015). Median values and ranges were N1 (𝑛 = 3),
0.24min−1 and 0.17∼0.26min−1; N2 (𝑛 = 17), 0.29min−1
and 0.17∼0.46min−1; N3 (𝑛 = 6), 0.46min−1 and 0.29∼
0.70min−1, respectively (Figure 1). 𝑘ep and Ve in the largest
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Table 1: Patient demographic data and tumor characteristics (𝑁 =
26).
Baseline characteristics
Age (years)
Range 25∼67
Median 45
Mean ± SD 45 ± 12
Sex
Number of female patients 7
Number of male patients 19
Stage
T stage Number of patients
1 10
2 5
3 9
4 2
N stage Number of patients
1 3
2 17
3 6
M stage Number of patients
0 25
1 1
Notes. Age (years)is patient age at diagnosis; T, N, and M stages were
evaluated according to the American Joint Committee on Cancer (AJCC)
staging system.
Median values and ranges were N1 (𝑛 = 3), 0.24min−1 and 0.17∼0.26min−1;
N2 (𝑛 = 17), 0.29min−1 and 0.17∼0.46min−1; N3 (𝑛 = 6), 0.46min−1 and
0.29∼0.70min−1, respectively (Figure 1). 𝑘ep and ve in the largest node were
not correlated with N stage (𝑃 = 0.485 and 0.113, resp.). The median values
and ranges of 𝑘ep were N1, 0.44min
−1 and 0.33∼0.66min−1; N2, 0.38min−1
and 0.13∼0.67min−1; N3, 0.36min−1 and 0.10∼0.63min−1, respectively. The
median values and ranges of ve were N1, 0.32 and 0.29∼0.70; N2, 0.39 and
0.32∼0.60; N3, 0.40 and 0.24∼0.62, respectively.
Table 2: The perfusion parameters of metastatic nodes among N
stages (𝑛 = 26).
N stage 𝐾trans (min−1) 𝑘ep (min
−1) Ve
N1 (𝑛 = 3) 0.24 (0.17∼0.26) 0.44 (0.33∼0.66) 0.32 (0.29∼0.70)
N2 (𝑛 = 17) 0.29 (0.17∼0.46) 0.38 (0.13∼0. 67) 0.39 (0.32∼0.60)
N3 (𝑛 = 6) 0.46 (0.29∼0.70) 0.36 (0.10∼0.63) 0.40 (0.24∼0.62)
node were not correlated with N stage (𝑃 = 0.485 and
0.113, resp.). The median values and ranges of 𝑘ep were N1,
0.44min−1 and 0.33∼0.66min−1; N2, 0.38min−1 and 0.13∼
0.67min−1; N3, 0.36min−1 and 0.10∼0.63min−1, respectively.
The median values and ranges of Ve were N1, 0.32 and
0.29∼0.70; N2, 0.39 and 0.32∼0.60; N3, 0.40 and 0.24∼0.62,
respectively (Table 2).
The mean values and ranges of 𝐾trans, 𝑘ep, and Ve in
the primary tumors were 0.27min−1 and 0.16∼0.48min−1;
0.62min−1 and 0.25∼1.06min−1; 0.37 and 0.25∼0.60, respec-
tively. Using Spearman’s correlation, none of the three DCE-
MRI parameters in nodes were significantly correlated with
the corresponding parameters in the primary tumors: for
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Figure 1: Box plots showing significant difference of 𝐾trans in
metastatic nodes by Kruskal-Wallis test among N staging (𝑃 =
0.015).
𝐾
trans, 𝑟 = 0.224 and 𝑃 = 0.272; for 𝑘ep, 𝑟 = 0.134 and
𝑃 = 0.515; for Ve, 𝑟 = 0.177 and 𝑃 = 0.387 (Figure 2).
4. Discussion
In this study, we evaluated the correlation between the DCE-
MRI parameters in the metastatic lymph nodes and tumor
N stage. Studies have been performed to compare the DCE-
MRI parameters in lymph nodes that were confirmed to be
positive and negative for malignancy by histology [15, 16].
Such studies have showed that malignant nodes have higher
vascularity andmicrovessel permeability compared to benign
nodes. Similarly, our findings also support the hypothesis that
increased vascular permeability reflected by 𝐾trans in meta-
static lymph nodes is positively correlated with N stage; that
is, the higher the N stage, which is an indicator of aggres-
siveness and portends poorer prognosis [4, 17], the higher the
𝐾
trans, which reflects higher permeability and perfusion. Such
significant correlation should not be due to the nodal size,
since the correlation between these perfusion parameters and
nodal size was insignificant. It is widely accepted that these
perfusion and permeability characteristics reflected by DCE-
MRI are directly related to the tumor angiogenic activity [18–
20] and that tumor N staging reflects the spread and extent
of lymph node metastasis [10]. Based on the fact that angio-
genesis is required to support cancer growth and metastasis,
our results may be explained by the fact that nodes withmore
angiogenesis facilitate the spread of cancer cells in lymph
node chains leading to a higher N stage.
We did not observe any significant difference in Ve or
𝑘ep among tumors of different N stages. The 𝑘ep, calculated
as 𝐾trans/Ve, is not an independent parameter; Ve is the
measurement of volume of EES per unit volume of tissue and
reflects the available space for contrast permeability.The lack
of significance in the difference between Ve may indicate that
the higher 𝐾trans may be due mainly to the increased blood
flow (perfusion) but not the EES volume, and that the increase
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Figure 2: Scatter plots show no significant correlations between the DCE-MRI parameters in metastatic nodes and in primary tumors by
Spearman’s correlation: (a)𝐾tran; (b) 𝑘ep; (c) Ve.
in 𝐾trans may precede the increase in EES volume. Further
prospective studies are required to confirm this finding.
The present study found that theDCE-MRI parameters in
nodes were not significantly correlated with the correspond-
ing parameters in primary tumors, similar to another study
performed in cervical cancers and its nodal metastases [8].
This suggests that the tumor microvessel environment, that
is, perfusion and vascular permeability, in the primary NPC
tumor is independent of the characteristics in its metastatic
lymph nodes.Thus, tumors with high perfusion and vascular
permeability may neither develop nodal metastasis nor have
more metastatic nodes. This discrepant finding between the
primary tumor and its metastasis suggests heterogeneity that
is intermetastatic and supports the notion that themetastasiz-
ing process of a malignant primary tumor may be related to
genetic alterations in the primary tumor, which may be het-
erogeneous in nature [21, 22].The primary tumormay release
a number of cells into the circulation; however only a small
fraction of these cells establish metastases in a favourable
organ or node in a nondeterministic manner [23].Thereafter,
continual evolution of the primary tumor reflects local selec-
tive advantages rather than future selective advantages, and
thus growth at metastatic sties is not dependent on additional
genetic alterations in the primary tumor. Such discrepancy
between metastatic nodes and primary tumor indicates that
attention should also be needed to the study of themetastases.
The results of our study, although the mechanism of
which is still unclear, may have some clinical implications
for clinical management of NPC patients. Since the perfusion
parameters in nodes, but not in primary lesion, were signifi-
cantly correlated with the tumor N stage, clinicians may pay
more attention to these parameters in metastatic nodes due
to the fact that N staging is critical in prognosis. On the other
hand, one may expect to evaluate the role of such perfusion
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parameters, which reflect the functional activity in tumors
and metastatic nodes, in NPC patient management in the
future studies.
Our study has some limitations. Firstly, theMRI scan cov-
erage included the primary tumor and upper neck but not the
entire neck.Thus, some regionalmetastatic lymph nodesmay
not have been included. However, it has been reported that
lymphnodemetastasis generally spreads from the upper neck
to the lower neck [24–26]; therefore the first lymph node
station of spread is in the locoregional node adjacent to the
primary tumor. Secondly, there may be an element of error
in the placement of the ROI, as this procedure was completed
manually, although accuracywas improved by confirming the
location of the ROIs on the coregistered conventional T2W
images.
5. Conclusion
In a cohort of newNPC patients, we found that perfusion and
permeability based onDCE-MRI are higher in regional nodes
of higher N stage tumors, and that the parameters in the
nodes have no relationship with the corresponding param-
eters in its primary tumor. These findings showed that DCE-
MRI in the metastatic lymph plays a distinct role in char-
acterizing the nodal status in NPC. This finding, if further
verified, may have important impact in the staging and
management of NPC patients with metastatic lymph nodes.
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